Palvella Therapeutics (NASDAQ:PVLA) Downgraded by Wall Street Zen to “Sell”

Palvella Therapeutics (NASDAQ:PVLA) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other equities research analysts have also recently commented on PVLA. HC Wainwright lifted their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th. Canaccord Genuity Group lifted their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $198.07.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $127.12 on Friday. The stock has a fifty day moving average of $111.43 and a 200-day moving average of $94.86. The stock has a market capitalization of $1.82 billion, a P/E ratio of -34.26 and a beta of -0.21. Palvella Therapeutics has a 52 week low of $20.20 and a 52 week high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Tuesday, March 31st. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.13). Equities research analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Elaine J. Heron acquired 2,400 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, with a total value of $300,000.00. Following the completion of the purchase, the director directly owned 47,812 shares in the company, valued at approximately $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Group One Trading LLC lifted its holdings in Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Palvella Therapeutics by 11.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after acquiring an additional 433 shares in the last quarter. Archer Investment Corp bought a new position in Palvella Therapeutics during the third quarter worth about $28,000. Bank of America Corp DE lifted its holdings in Palvella Therapeutics by 12.3% during the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after acquiring an additional 515 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in Palvella Therapeutics by 8.7% during the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after acquiring an additional 528 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.